Press Releases


Latest News


Adamas Pharmaceuticals' Phase 2/3 Clinical Study Published in Movement Disorders
Feb 9, 2015 | General Releases

Adamas Pharmaceuticals Provides Review of 2014 and Previews Upcoming Business Drivers
Jan 11, 2015 | General Releases

Adamas Pharmaceuticals Receives $30 Million Milestone Payment From Actavis
Jan 8, 2015 | General Releases

Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride
Dec 24, 2014 | General Releases

Adamas Pharmaceuticals Issued Six Additional U.S. Patents
Dec 2, 2014 | General Releases

Adamas Pharmaceuticals to Present at Piper Jaffray Healthcare Conference
Nov 18, 2014 | General Releases

Adamas Pharmaceuticals to Present at 2014 Credit Suisse Healthcare Conference
Nov 5, 2014 | General Releases

Adamas Reports Third Quarter 2014 Financial Results
Nov 4, 2014 | Financial Releases

Adamas Pharmaceuticals Expands Its Phase 3 Program With ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) in Patients With Parkinson's Disease
Oct 28, 2014 | General Releases

Adamas Pharmaceuticals Announces Management Changes
Aug 13, 2014 | General Releases

Pages:  1 2 3 4 5 6 7 8 9 10 11